The Mechanisms of Action and the Role of Alpha Interferon in the Therapy of Myeloma

  • A. Österborg
  • H. Mellstedt
Part of the ESO Monographs book series (ESO MONOGRAPHS)


Intermittent high-dose melphalan/prednisone (MP) treatment [1] is regarded by many clinicians as first-line therapy for patients with multiple myeloma. The introduction of intensive combination chemotherapy has not been shown to consistently improve the response rate or to prolong survival [2,3]. Since the overall prognosis for myeloma patients is rather poor, there is a need for better treatment modalities.


Multiple Myeloma Myeloma Cell Alpha Interferon Hairy Cell Leukaemia Natural Killer Cell Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alexanian R, Haut A, Khan A et al: Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969 (208):1680–1685PubMedCrossRefGoogle Scholar
  2. 2.
    Sporn JR and Mclntyre OR: Chemotherapy of previously untreated multiple myeloma patients: An analysis of recent treatment results. Semin Oncol 1986 (13):318–325PubMedGoogle Scholar
  3. 3.
    Österborg A, Ahre A, Björkholm M et al: Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III — A randomized study from MGCS. Eur J Hematol 1989 (43):54–62CrossRefGoogle Scholar
  4. 4.
    Taylor JL, Sabran JL and Grossberg SE: The cellular effects of interferon. In: Came PE, Carter WA (eds) Interferons and Their Applications. Springer-Verlag, New York 1984 pp 169–205Google Scholar
  5. 5.
    Week PK and Came PE: Comparative biologic activities of human interferon. In: Came PE, Carter WA (eds) Interferons and Their Applications. Springer-Verlag, New York 1984 pp 339–357Google Scholar
  6. 6.
    Salmon SE and Ozer H: Alpha interferon therapy in oncology: Clinical update. Semin Oncol 1986 (13):1–2Google Scholar
  7. 7.
    Strander H: Interferon treament of human neoplasia. Adv Cancer Res 1986 (46):1–256PubMedCrossRefGoogle Scholar
  8. 8.
    Ratain MJ, Vardiman JW and Golomb HM: The role of interferon in the treatment of hairy cell leukemia. Semin Oncol 1986 (13):21–28PubMedGoogle Scholar
  9. 9.
    Talpaz M, McCredie KB, Mavligit GM and Gutterman JU: Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983 (62) :689–692PubMedGoogle Scholar
  10. 10.
    Aapro MS, Alberts DS and Salmon SE: Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 1983 (10):161–166PubMedCrossRefGoogle Scholar
  11. 11.
    Einhorn S, Femberg JO, Grandér D and Lewensohn R: Interferon exerts a cytotoxic effect on primary human myeloma cells. Eur J Cancer Clin Oncol 1988 (24):1505–1510PubMedCrossRefGoogle Scholar
  12. 12.
    Grandér D, von Stedingk LV, Wasserman J and Einhorn S: Influence of interferon on antibody production and viability of malignant cells from patients with multiple myeloma. Eur J Haematol 1991 (46):17–25PubMedCrossRefGoogle Scholar
  13. 13.
    Adams A, Strander H and Cantell K: Sensitivity of the Epstein-Barr virus transformed human lymphoid cell lines to interferon. J Gen Virol 1975 (28):207–217PubMedCrossRefGoogle Scholar
  14. 14.
    Einhorn S and Strander H: Interferon therapy for neoplastic diseases in man: In vitro and in vivo studies. Adv Exp Med Biol 1978 (110):159–174PubMedGoogle Scholar
  15. 15.
    Case DC, Somebom HL, Paul SD et al: Phase II study of rDNA alpha-2 interferon (Intron A) in patients with multiple myeloma utilizing an escalating induction phase. Cancer Treat Rep 1986 (70):1251–1254PubMedGoogle Scholar
  16. 16.
    Åhre A, Björkholm M, Österborg A et al: High doses of natural alpha-interferon (α-IFN) in the treatment of multiple myeloma. — A pilot study from the Myeloma Group of Central Sweden (MGCS). Eur J Haematol 1988 (41):123–130PubMedCrossRefGoogle Scholar
  17. 17.
    Cooper MR and Welander CE: Interferon in the treatment of multiple myeloma. Semin Oncol 1986 (13):334–340PubMedGoogle Scholar
  18. 18.
    Ehrsson H, Eksborg S, Wallin I, Österborg A and Mellstedt H: Oral melphalan pharmacokinetics — influence of interferon induced fever. Clin Pharmacother 1990 (47):86–90Google Scholar
  19. 19.
    Friedman RM: Growth factors, oncogenes, and interferon. J Exp Pathol 1986 (2):223–228PubMedGoogle Scholar
  20. 20.
    Paganelli KA, Evans SS, Han T and Ozer H: B cell growth factor-induced proliferation of hairy cell lymphocytes and inhibition by type 1 interferon in vitro. Blood 1986 (67):937–942PubMedGoogle Scholar
  21. 21.
    Asaoku H, Kawano M, Iwato K et al: Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma. Blood 1988 (2):429–432Google Scholar
  22. 22.
    Clemens M: Interferons and oncogenes. Nature 1985(313):531–532PubMedCrossRefGoogle Scholar
  23. 23.
    Pegoraro L, Malavesi F and Bellone G et al: The human myeloma cell line LP-1: A versatile model in which to study early plasma cell differentiation and c-myc activation. Blood 1989 (73):1020–1027PubMedGoogle Scholar
  24. 24.
    Krolewski JJ and Dalla-Favera R: Oncogenes and their relevance in the pathogenesis of hematologic malignancies. In: Luzzatto L, Mauer AM (eds) Education Book. Milan: XXII. Internat Congr of Hematol. 28 Aug – 3 Sept, 1988 pp 20–28Google Scholar
  25. 25.
    Gazdar AF, Oie HK, Kirsch IR and Hollis GF: Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood 1986 (67):1542–1549PubMedGoogle Scholar
  26. 26.
    Österborg A, Nilsson B, Björkholm M, Holm G and Mellstedt H: Natural killer cell activity in monoclonal gammopathies: Relation to disease activity. Eur J Haematol 1990 (45):153–157PubMedCrossRefGoogle Scholar
  27. 27.
    Einhorn S, Ahre A, Blomgren H et al: Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon induced enhancement of natural killer activity and clinical response to human interferon-alpha. Int J Cancer 1982 (30): 167–172PubMedCrossRefGoogle Scholar
  28. 28.
    Flood PM, Phillips C, Taupier MA and Schreiber H: Regulation of myeloma growth in vitro by idiotype-specific T lymphocytes. J Immunol 1980 (124):424–430PubMedGoogle Scholar
  29. 29.
    Lindahl P, Leary P and Gresser I: Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci USA 1972 (69):1721–1725CrossRefGoogle Scholar
  30. 30.
    Lindahl P, Gresser I, Leary P and Tovey M: Interferon treatment of mice: enhanced expression of histocompatibility antigens on lymphoid cells. Proc Natl Acad Sci USA 1976 (73):1284–1287PubMedCrossRefGoogle Scholar
  31. 31.
    Tötterman TH, Danersund A, Carlsson M and Nilsson K: Effect of recombinant interferon-alpha and gamma on B-CLL cells in serum-free medium: Expression of activation, differentiation, and CALLA antigens. Leukemia 1987 (1):667–679PubMedGoogle Scholar
  32. 32.
    Mellstedt H, Holm G and Björkholm M: Multiple myeloma, Waldenstrom’s macroglobulinemia and benign monoclonal gammopathy. Characteristics of the B cell clone, immunoregulatory cell populations and clinical implications. Adv Cancer Res 1984 (41): 257–289PubMedCrossRefGoogle Scholar
  33. 33.
    Mellstedt H, Killander D and Pettersson D: Bone marrow kinetic studies on three patients with myelomatosis. Indications for malignant proliferation within both the plasma cell and lymphoid cell compartments. Acta Med Scand 1977 (202):413–417PubMedCrossRefGoogle Scholar
  34. 34.
    Chan C, Wormsley SB, Pierce LE, Peter JB and Schechter GP: B-cell surface phenotypes of proliferating myeloma cells: Target antigens for immunotherapy. Am J Hematol 1989 (33):101–109CrossRefGoogle Scholar
  35. 35.
    Åhre A, Bjrkholm M, Mellstedt H et al: Human leukocyte interferon and intermittent high dose melphalan/prednisolone administration in the treatment of multiple myeloma. A randomized clinical trial. Cancer Treat Rep 1984 (68):1331–1338PubMedGoogle Scholar
  36. 36.
    Mellstedt H, for the Myeloma Group of Central Sweden (MGCS): MP/alpha-IFN in the induction treatment of multiple myeloma and as maintenance therapy. — A randomized trial from MGCS. Abstract. Illrd International Workshop on Multiple Myeloma, Torino, April 9-12,1991Google Scholar
  37. 37.
    Österborg A and Mellstedt H: Induction therapy with interferon in multiple myeloma and possible mechanisms of action. In: Gutterman J, Talpaz M (eds) Biological Response Modifiers in Hematological Malignancies. Marcel Dekker Inc, New York 1990 (in press)Google Scholar
  38. 38.
    Ohno R and Kimura K: Treatment of multiple myeloma with recombinant interferon alfa-2a. Cancer 1986 (57):1685–1688PubMedCrossRefGoogle Scholar
  39. 39.
    Ludwig H, Cortelezzi A, Scheithauer W et al: Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial. Eur J Cancer Clin Oncol 1986 (22):1111–1116PubMedCrossRefGoogle Scholar
  40. 40.
    Montuoro A, De Rosa L and De Blasio A: Alpha-2-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma: Preliminary results. Abstract. XXII. Intemat Congr of Hematol, 28 Aug-3 Sept, Milan, Italy 1988Google Scholar
  41. 41.
    Corrado C, Pavlovsky S, Saslasky J et al: Randomized trial comparing melphalan-prednisone with or without recombinant alpha 2 interferon (r-alpha-2-IFN) in multiple myeloma. Proc Am Soc Clin Oncol (ASCO) 1989 (8):258 (abstr)Google Scholar
  42. 42.
    Cooper MD: Melphalan/Prednisone with and without alfa 2b interferon (IFN) in newly diagnosed multiple myeloma. 15th Int Cancer Congr, 16-22 Aug, Hamburg, Germany 1990, p 986 (abstract)Google Scholar
  43. 43.
    Kyle RA, Oken MM, Greipp PR, Kay NE and Tsiatis A: VBMCP/rlFN alpha 2 induction therapy in multiple myeloma. Vth Hannover Interferon Workshop, 21-23 February 1990, p 46 (abstr)Google Scholar
  44. 44.
    Ludwig J, Preis P, Scheithauer W et al: Interferon-alpha-2 (rIFN) with or without chemotherapy in newly-diagnosed patients with multiple myeloma. Proc Am Soc Clin Oncol (ASCO) 1989, A1080 (abstr)Google Scholar
  45. 45.
    Mandelli F, Avvisati G, Amadori S et al: Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990 (20): 1430–1434CrossRefGoogle Scholar
  46. 46.
    Westin J, Cortelezzi A, Hjort M, et al: Interferon-alfa-2b therapy during the plateau phase of multiple myeloma. Vth Hannover Interferon Workshop 21-23 February 1990, p 50 (abstr)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • A. Österborg
    • 1
  • H. Mellstedt
    • 1
  1. 1.Department of Oncology (Radiumhemmet)Karolinska HospitalStockholmSweden

Personalised recommendations